Elite Pharmaceuticals, Inc.
corporate_fare Company Profile
Elite Pharmaceuticals, Inc. (OTC:ELTP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for ELTP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for ELTP spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Elite Pharma Q2 Revenue Climbs 10% to $40.1M, Operating Income Up 21%
- Elite Q2 Revenue Up 10% to $40.1M, But Six-Month Gross Margin Falls to 41% and Material Weaknesses Persist
- Elite Pharmaceuticals Q1 FY2027 Revenue Falls 19.5% to $32.4M; Net Income $5.9M
- Elite Pharmaceuticals Q1 FY2027: Revenue Falls 19.5%, Material Weaknesses Disclosed
- Elite Pharma Reports 77% Revenue Growth, 151% Operating Income Surge for FY26
Financial Snapshot
Short Interest & Short Volume
2.76 days to coverFINRA reported short interest of 2,991,818 shares in ELTP as of the October 30, 2026 settlement, a 1.4% decrease from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 61.2% of ELTP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.